Business
Positive FDA Feedback to Progress Bexmarilimab
Positive FDA Feedback to Progress Bexmarilimab.
About this update from Faron Pharmaceuticals Oy
[{"type":"text","content":"\n \n \n \n Faron Pharmaceuticals Oy\n \n \n \n (\"Faron\" or the \"Company\")\n \n \n Inside Information: Faron Announces Positive US Food and Drug Administration (FDA) Feedback to Progress Bexmarilimab as a Monotherapy in Solid Tumors\n \n \n · Green light for continued clinical development after data package review\n \n · Alignment with company's selection of 1 mg/kg IV once-every-3-weeks (Q3W) as dose for further evaluation\n \n ·\n Supportive of biomarker-driven approach with CLEVER-1 staining of tumor biopsy\n \n Company announcement, March 22, 2023 at 03:00 AM (EDT) / 07:00 AM (GMT) / 09:00 AM (EET)\n \n \n Inside information\n \n TURKU, FINLAND / BOSTON, MA - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), a clinical stage biopharmaceutical company focused on tackling difficult-to-treat cancers, announces positive FDA feedback and recommendations for the future development of bexmarilimab as a monotherapy in multiple solid tumors. The agency's advice follows an end-of-Phase I/II meeting this month. The Phase I/II MATINS trial is investigating bexmarilimab, Faron's wholly owned precision immunotherapy asset, in multiple cancer indications.\n The official meeting minutes are consistent with the FDA's Project Optimus initiative to reform dose optimization and the selection paradigm in oncology drug development, which MATINS sought to comply with through multiple dose and indication arms of the study. FDA provided the following positive meeting feedback which further aligns the agency's views on bexmarilimab with the Company's, including:\n \n · Completed toxicology studies are adequate to support further clinical development of single-agent (monotherapy) bexmarilimab into a registration trial\n \n · Selection of 1 mg/kg IV Q3W as dose for further evaluation appears reasonable, although additional data are required to establish the recommended Phase II/III dose for specific cancer(s)\n \n · Valuable feedback and guidance on further development of a simple, validated staining assay to identify patients with CLEVER-1 positive tumors for clinical trial inclusion\n \"We are pleased to have received these positive and supportive FDA recommendations for the continued clinical development of bexmarilimab as a monotherapy in solid tumors,\" said CEO Markku Jalkanen. \"As a first-in-human study for bexmarilimab, MATIN...